安定した変異性p53に対する腫瘍依存を治療のために利用することによって生存率を改善する
E M Alexandrova1, A R Yallowitz1, D Li1
1Department of Pathology, Stony Brook University, Stony Brook, New York 11794, USA.
Nature
|May 27, 2015
まとめ
ミッセンスの変異性p53 (mutp53) タンパク質は,がんの進行と化学抵抗を駆動する. HSP90/HDAC6によって安定したmutp53をターゲットにすることで,腫瘍の成長を効果的に減少させ,臨床前のモデルで生存期間を延長します.
科学分野:
- 腫瘍学 腫瘍学
- 分子生物学は分子生物学である.
- 癌の遺伝学 癌の遺伝学
背景:
- p53のミッセンスの変異は,腫瘍抑制機能と腫瘍性機能獲得活動が廃止された異常なタンパク質を生成します.
- 変異性p53 (mutp53) タンパク質は,腫瘍で構成的に安定し,悪性腫瘍の進行,侵入,転移,および化学抵抗を促進します.
- 現在,世界中で1100万人の患者が,高度に安定したmutp53を発現する腫瘍を患っていますが,その治療的標的は,体内では未知のままです.
研究 の 目的:
- 変異したp53 (mutp53) が in vivo で有効な治療標的であるかどうかを調査する.
- ミュットp53の安定化におけるHSP90/HDAC6チャペロン機構の役割を決定し,治療戦略としてHSP90の抑制を調査する.
主な方法:
- タモキシフェン誘発のmutp53除去のために,新しいmutp53マウスモデル (R248Qホットスポット変異,floxQ) を利用しました.
- HSP90阻害剤 (17DMAG+SAHA,ganetespib) をmutp53およびp53をマウスに投与した.
- 腫瘍の成長,動物の生存,アポトーシス,T細胞リンパマゲネシスを評価した.
主要な成果:
- タモキシフェン誘発のmutp53アブレーションは,腫瘍の成長を抑制し,動物の生存率を37%増加させ,高度な腫瘍ではアポトーシスおよび回帰を誘発した.
- 長期にわたるHSP90阻害は,mutp53マウス (Q/- 59%,H/H 48%) の生存期間を大幅に延長したが,p53の littermates はそうではなかった.
- 薬剤の活性性は,mutp53の分解,腫瘍アポトーシス,T細胞リンパ変異の予防と相関していた.
結論:
- 持続的なmutp53発現は,腫瘍の維持と進行に不可欠です.
- HSP90/HDAC6機械は,mutp53の安定化の重要な決定要因である.
- 変異性p53は,HSP90の抑制が重要な治療の可能性を示し,実行可能な,がん特異的な薬標的です.
関連する概念動画
Abnormal Proliferation
5.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Targeted Cancer Therapies
9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.2K
Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Cancer-Critical Genes II: Tumor Suppressor Genes
10.2K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.2K
Drugs that Destabilize Microtubules
4.3K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.3K
Drugs that Stabilize Microtubules
2.9K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K


